Blood cancer drug venetoclax could potentially be used to deplete HIV latently infected cells and delay viral rebound, leading to a potential cure for HIV, according to a study from researchers in Australia who tested the drug in humanized mice models. Read More
Throughout the body, the vasculature and the nervous system are fellow travelers. Renaissance physician and anatomist Andreas Vesalius described their proximity on the macroanatomical level in the 16th century, and modern microscopic techniques have shown that it extends into the micrometer range – where there is a blood vessel, there is often a nerve nearby, and vice versa. Read More
Epidermal growth factor receptor (EGFR) is involved in cell proliferation leading to malignant transformation, and for that it is considered a therapeutic target for treatment and prevention in lung and other cancers. Read More
Medicines for Malaria Venture (MMV) has launched a call for new chemical compounds to screen against malaria through its MMV open innovation (MMVoi) initiative. Submissions from both industry and academia allow for compounds that have already been synthesized but not yet tested against malaria to be identified. Read More
A DE Shaw Research LLC patent reports N3-substituted uracil compounds acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists. As such, they are reported to be useful for the treatment of pain, fibrosis, autoimmune disease, neurological, dermatological, cardiovascular, respiratory and gastrointestinal disorders, among others. Read More
Researchers from Bristol Myers Squibb Co. presented the discovery of novel Toll-like receptor 7 (TLR7) agonists as potential new anticancer agents. Read More
Twist Bioscience Corp. has established a drug discovery agreement with Ono Pharmaceutical Co. Ltd. to discover and develop novel antibodies for the treatment of autoimmune diseases. Read More
Wistar Institute of Anatomy & Biology has synthesized new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors for the treatment of SARS-CoV-2 infection (COVID-19). Read More
Researchers from Guangdong Pharmaceutical University and affiliated organizations have discovered novel farnesoid X receptor (FXR) agonists as candidates for the treatment of nonalcoholic steatohepatitis (NASH). Read More
Research at Aurigene Oncology Ltd. has led to the identification of fused bicyclic heterocyclyl compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors and reported to be useful for the treatment of cancer. Read More
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented imidazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists. They are reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and ocular disorders. Read More
Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate immunity by acting both as a scaffolding protein and a protein kinase, and its overactivation correlates with several autoimmune disorders. Read More
Purdue Research Foundation has prepared and tested new peptides acting as N-terminal Xaa-Pro-Lys N-methyltransferase 1 (NTMT1) inhibitors reported to be useful for the treatment of cancer. Read More
